Background and objective: the study analysed the effectiveness and safety of warfarin use compared with warfarin nonuse and non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients aged ≥65 years. Methods: after searching PubMed and the Cochrane Library, 26 studies were included, with 10 comparing warfarin with warfarin non-use and 16 comparing warfarin with NOACs, in older AF patients (≥65 years). Results: warfarin use was superior to no antithrombotic therapy [relative risk (RR) 0.59, 95% confidence interval (CI) 0.51-0.76, I 2 = 12.3%, n = 8] and aspirin (RR 0.44, 95% CI 0.24-0.64, I 2 = 0.0%, n = 5) for stroke/thromboembolism (TE) prevention. Warfarin use was associated with a non-significant increase in risk of major bleeding compared with no antithrombotic therapy (RR 1.26, 95% CI 0.99-1.52, I 2 = 0.0%, n = 7) and aspirin (RR 1.20, 95% CI 0.91-1.50, I 2 = 0.0%, n = 5). NOACs were superior to warfarin for stroke/TE prevention [hazard ratio (HR) 0.81, 95% CI 0.73-0.89, I 2 = 56.6%, n = 9], and also were associated with reduced risk of major bleeding compared to warfarin (HR 0.87, I 2 = 86.1%, n = 9). Conclusions: warfarin use was superior to warfarin non-use, aspirin and no antithrombotic therapy in reducing the risk of stroke/TE in older AF patients, but with a possible increase in major bleeding. NOACs were superior to warfarin for stroke/TE prevention, with reduced risk of major bleeding.
Introduction
Atrial fibrillation (AF) prevalence increases with age, increasing from 0.1% at age <35 years to 2.8% at age >65 years old [1, 2] . AF increases the risk of stroke by 5-fold [3] , and the risk is even higher in those aged ≥65 years. Warfarin use reduces the risk of stroke by around twothirds in AF patients [4] , but risk of bleeding is increased in subjects over 80 years of age [5] . In clinical practice warfarin is used less frequently in very elderly subjects; for example, warfarin use reduced from 70.2% in those aged 65-70 years to 38.9% in those older than 95 years [6] . Instead, an increasing trend of aspirin use has been seen in older AF patients [7] .
Recently, non-vitamin K antagonist oral anticoagulants [NOACs; sometimes referred to as direct oral anticoagulants (DOACs)] have been shown not to be inferior to vitamin K antagonists (VKAs; e.g. warfarin) for the prevention of stroke/systematic thromboembolism (TE) and risk of major bleeding both in real-world studies and in randomised controlled trials (RCTs) [8] [9] [10] . However it is not clear whether the effectiveness and safety profile is the same in older AF patients.
This study was performed to determine the effectiveness and safety of warfarin use in comparison with non-warfarin use (including aspirin and no antithrombotic therapy), as well as with the NOACs. Weighted regression of relative risk (RR) for the comparison of warfarin versus nonwarfarin was performed. Second, the adjusted hazard ratio (HR) for comparison of NOACs versus warfarin with increasing age was also calculated.
Methods

Search strategy and selection criteria
We followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and the reporting Meta-analyses of Observational Studies in Epidemiology (MOOSE) when performing this meta-analysis [11, 12] . A comprehensive literature search of PubMed and the Cochrane Library was performed by two independent reviewers (Y.B. and S-D.G.) using the following items 'atrial fibrillation', 'AF', 'apixaban', 'rivaroxaban', 'dabigatran', 'edoxaban', 'warfarin', 'NOACs', 'DOACs', 'aspirin' and 'elderly' from 1 January 2000 to 14 December 2016. The lists of references were also reviewed in eligible studies. Any discrepancies were referred to a third reviewer (H.D.) by reevaluation to reach consensus. To be included in the metaanalysis, studies needed to meet the following requirements. Other outcomes of mortality and intracranial haemorrhage (ICH) were also extracted from the original papers. For studies that did not report combined stroke and TE, separate ischaemic stroke, stroke or TE was used for the meta-analysis instead.
In comparison of warfarin with NOACs, papers with adjusted HRs were included for preference, or else the crude RR was used instead. With regard to the comparisons of warfarin with no antithrombotic therapy or aspirin, any paper which reported risk estimates of HRs, RRs or odds ratios or which provided data for the calculation of risk estimates was included.
The main published study of duplicate studies from the same cohort was included in our analysis. No restriction on study size was defined in our analysis. Studies were excluded if exact data could not be inferred from the figures available. Papers without comparisons among OACs were excluded. Abstracts, editorials, case reports, reviews and case series were also excluded. Quality was assessed using the Newcastle-Ottawa scale, and those with scores >6 were included in the study [13] .
Statistical analysis
The analysis was conducted using STATA, version 12.0 (Stata Corp.). Event rates of various outcomes were evaluated using count of events/person-years of observation. Risk estimates with 95% confidence intervals (95% CIs) were used to measure the effect sizes in our study. The adjusted risk estimate was considered first, or, if this was not available, the unadjusted risk estimate was used for analysis. If both were unavailable, the risk estimate was calculated using event number, person-years or other available data. First, we used a fixed model, and then a random effects model if there was heterogeneity according to the I 2 index [14] . Values of ≤25, 25-50 and ≥50% were defined as low, moderate and high degrees of heterogeneity, respectively. Funnel plots with Begg's correlation test and Egger's regression test were used to assess publication bias [15, 16] .
We analysed the effectiveness (stroke/TE) and safety (major bleeding, mortality) risk estimates between warfarin and non-warfarin using two-variable linear regression. We performed sensitivity analysis by analysing warfarin versus no antithrombotic therapy or aspirin separately.
Results
A total of 1,315 studies were initially identified (comprising 1,234 online and 81 from references). After screening titles and abstracts, we excluded 1,118 papers, and 197 remained for a detailed evaluation. Of these studies, 171 were excluded as they did not meet the inclusion criteria (30 reviews and meta-analyses; 68 papers without extracted outcomes for older people; 5 papers without outcomes of interest; 16 papers without outcomes with OACs; 12 no comparison of warfarin versus non-warfarin; 17 with mixed diseases other than AF, 2 papers compared OAC versus non-OAC; and 21 with duplicate studies).
Finally, 26 studies were included in our analysis, comprising 10 randomised trials and 16 observational studies: one compared warfarin versus no antithrombotic therapy; [17] four compared warfarin versus aspirin; [18] [19] [20] [21] two compared warfarin versus no antithrombotic therapy and warfarin versus aspirin in the same papers; [22, 23] three compared warfarin versus no-warfarin; [24] [25] [26] Warfarin reduced mortality compared with warfarin non-use, no antithrombotic therapy or aspirin in older AF patients (see Supplementary data, Supplementary Figure  S2 , available at Age and Ageing online), but increased risk of ICH compared with no antithrombotic therapy (RR 3.38, 95% CI 1.86-6.14, n = 1) [17] .
Comparisons of NOACs with warfarin
NOACs were superior to warfarin in reducing the risk of stroke/TE (HR 0.81, 95% CI 0.73-0.89, I 2 = 56.6%, n = 9) in older AF patients (age ≥65 years) (Figure 2A ). The risk of major bleeding with NOACs was lower than with warfarin (HR 0.87, 95% CI 0.77-0.97, I 2 = 86.1%, n = 9) ( Figure 2B ). NOACs were associated with reduced risk of mortality (HR 0.82, 95% CI 0.74-0.90, I 2 = 61.3%, n = 5) compared with warfarin (see Supplementary data, Supplementary Figure S3 , available in Age and Ageing online).
Trends of benefits and risks with increasing age
For the risk of stroke/TE, warfarin use was superior to warfarin non-use, with no significant increase in RR with increasing age (r 2 = 0.05, P = 0.35) ( Figure 3A) ; the RR with warfarin compared with aspirin was attenuated with increasing age (r 2 = 0.76, P = 0.002) (Supplementary Figure S4A available in Age and Ageing online). The RR of major bleeding was not increased with higher age with warfarin compared with warfarin non-use, with a stable RR (r 2 = 0.007, P = 0.73) ( Figure 3B) ; the RR was not significantly decreased with increasing age in the comparisons of warfarin versus aspirin (r 2 = 0.20, P = 0.22) (Supplementary Figure S4B available in Age and Ageing online). Higher age had no significant association with RR for mortality with warfarin compared with warfarin non-use (r 2 = 0.008, P = 0.75) ( Figure 3C ) and aspirin (r 2 = 0.21, P = 0.54) (Supplementary Figure S4C available in Age and Ageing online).
When compared with warfarin, NOACs showed decreased HR of stroke/TE with increasing age, (r 2 = 0.23, P = 0.01) , with an attenuation in the reduction in HR for major bleeding (r 2 = 0.20, P = 0.02) and mortality (r 2 = 0.23, P = 0.05) with increasing age (Figure 3D-F) . When a separate comparison of dabigatran, apixaban and rivaroxaban with warfarin was performed, the risk trends were broadly consistent with the overall NOAC comparisons (Supplementary Figure S5 available in Age and Ageing online).
Subgroup and sensitivity analyses
As publication bias could be seen according to Egger's regression test (P = 0.002) (Supplementary Table S6, available 
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and with reduced risk of major bleeding in older AF patients, increasing age was associated with greater RR reduction of stroke/TE, but with attenuation of the reduction in risk of major bleeding.
Our results show consistency for the risks of stroke/TE between RCTs and real-world studies, but were discordant in the risk of major bleeding. There are clear differences between real-world studies and RCTs, such as different inclusion/ exclusion criteria, follow-up period and perhaps different population characteristics. Another possible explanation was that some differences may exist between the four NOACs, dabigatran, apixaban, rivaroxaban and edoxaban, according to head to head comparisons in real-world studies [43, 44] . However, these 'real-world' comparisons should be interpreted with caution, and are no substitute for rigorous RCT comparisons.
The NOACs were superior to warfarin in reducing the risk of stroke/TE, and mortality in older AF patients, and were associated with reduced risk of major bleeding. The results were broadly similar to previous comparisons of 
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NOACs against warfarin; [45] however, this is one of the first studies focused on elderly patients providing comparisons between warfarin and the different antithrombotic strategies. The novelty of the present study is that it explores the effect of age on benefits and risks.
Data on the risks of ICH, which is the most feared complication in older AF patients receiving anticoagulants, were limited between warfarin and non-warfarin comparisons, so we could not perform meta-regression on its risk trends. Based on the three studies available on older people, warfarin use was associated with increased risk of ICH compared with warfarin non-use.
Limitations
There are several limitations and strengths of this study. First, some data were crudely estimated or excluded [46] because we do not have access to the original data despite attempts to contact the study authors. Second, publication bias was evident for the risk of stroke/TE between NOACs and warfarin, but disappeared when subgroup analysis of RCTs was performed. Third, confoundings were minimised through using the adjusted HR for the comparisons of NOACs and warfarin. Fourth, although RRs without adjustment were used in the comparison of warfarin use and warfarin non-use (including aspirin and no antithrombotic therapy), low heterogeneity among studies was evident, strengthening the analysis.
Conclusions
Warfarin use was superior to warfarin non-use, aspirin and no antithrombotic therapy in reducing the risk of stroke/ TE. The NOACs were superior to warfarin for stroke/TE prevention with reduced risk of major bleeding in older AF patients.
Key points
• Warfarin use was superior to warfarin non-use, aspirin and no antithrombotic therapy in reducing the risk of stroke/TE in older patients with AF.
• The non-vitamin K antagonist oral anticoagulants (NOACs) were superior to warfarin for stroke/TE prevention with reduced risk of major bleeding in older AF patients.
• This study adds to the evidence suggesting that NOACs should be preferred to warfarin as oral anticoagulants for stroke prevention in older people with AF.
Supplementary data
Supplementary data are available in Age and Ageing online.
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